695188-21-7

Basic information

• Product Name: 4-Bromo-3-fluorobenzoyl chloride
• Synonyms: 4-Bromo-3-fluorobenzoyl chloride
• CAS NO: 695188-21-7
• Molecular Formula: C₇H₃BrClFO
• Molecular Weight: 237.4535232
• Mol File: 695188-21-7.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 246.1°C at 760 mmHg
• Flash Point: 102.6°C
• Appearance: /
• Density: 1.742g/cm³
• Vapor Pressure: 0.0276mmHg at 25°C
• Refractive Index: 1.561
• CAS DataBase Reference: 4-Bromo-3-fluorobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-3-fluorobenzoyl chloride(695188-21-7)
• EPA Substance Registry System: 4-Bromo-3-fluorobenzoyl chloride(695188-21-7)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 695188-21-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-Bromo-3-fluorobenzoyl chloride is used as a reagent in chemical synthesis for the preparation of various organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
4-Bromo-3-fluorobenzoyl chloride is used as an intermediate in the synthesis of pharmaceutical compounds. Its properties allow for the creation of new drug molecules with potential therapeutic applications.
Used in Material Science:
4-Bromo-3-fluorobenzoyl chloride is used as a building block in the development of new materials with specific properties, such as improved thermal stability or chemical resistance, which can be utilized in various industries.
Used in Research and Development:
4-Bromo-3-fluorobenzoyl chloride is used as a research compound in academic and industrial laboratories to study its chemical properties and potential applications in various fields, including chemistry, materials science, and pharmaceuticals.

InChI:InChI=1/C7H3BrClFO/c8-5-2-1-4(7(9)11)3-6(5)10/h1-3H

Upstream product

• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 136434-77-0 4-bromo-3-fluoroiodobenzene 

Downstream Products

• 760192-85-6 (4-bromo-3-fluorophenyl)[4-(methyloxy)phenyl]methanone 
• 935855-06-4 4-bromo-N-(3,5-dimethyl-isoxazol-4-ylmethyl)-3-fluoro-benzamide 
• 343564-56-7 4-bromo-3-fluoro-N-methoxy-N-methyl-benzamide 
• 1160219-31-7 4-bromo-3-fluoro-N-(6-methylpyridin-2-yl)benzamide 
• 1620074-87-4 C₁₄H₁₅BrFNO₃ 
• 1620677-19-1 4-bromo-N-(4-cyanopyridin-2-yl)-3-fluorobenzamide 
• 1620677-32-8 4-bromo-N-(4-(difluoromethyl)pyridin-2-yl)-3-fluorobenzamide 
• 1415758-93-8 (S)-tert-butyl 2-(4-(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carboxamido)-3-fluorophenyl)morpholine-4-carboxylate 
• 1415757-58-2 (S)-tert-butyl 2-(4-(1-(3-(difluoromethoxy)phenyl)-1H-pyrazole-4-carboxamido)-3-fluorophenyl)morpholine-4-carboxylate 
• 1415756-24-9 2-methyl-5-phenyl-2H-pyrazole-3-carboxylic acid ((R)-2-fluoro-4-morpholin-2-yl-phenyl)amide 
• 1415756-03-4 6-fluoro-1H-indazole-3-carboxylic acid ((R)-2-fluoro-4-morpholin-2-yl-phenyl)amide 
• 1415757-59-3 (S)-2-{4-[(4-Cyano-pyridine-2-carbonyl)-amino]-3-fluoro-phenyl}-morpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR

Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition c

NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING

The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) cau

Metathesis-active ligands enable a catalytic functional group metathesis between aroyl chlorides and aryl iodides

Current methods for functional group interconversion have, for the most part, relied on relatively strong driving forces which often require highly reactive reagents to generate irreversibly a desired product in high yield and selectivity. These approaches generally prevent the use of the same catalytic strategy to perform the reverse reaction. Here we describe a catalytic functional group metathesis approach to interconvert, under CO-free conditions, two synthetically important classes of electrophiles that are often employed in the preparation of pharmaceuticals and agrochemicals—aroyl chlorides (ArCOCl) and aryl iodides (ArI). Our reaction design relies on the implementation of a key reversible ligand C–P bond cleavage event, which enables a non-innocent, metathesis-active phosphine ligand to mediate a rapid aryl group transfer between the two different electrophiles. Beyond enabling a practical and safer approach to the interconversion of ArCOCl and ArI, this type of ligand non-innocence provides a blueprint for the development of a broad range of functional group metathesis reactions employing synthetically relevant aryl electrophiles.

PIPERIDINE COMPOUNDS AS PCSK9 INHIBITORS

One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.

BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY

A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis

Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases. We report a series of compounds based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity. Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket. These interactions are evident in the X-ray crystal structure of the lead compounds 1 and 3 in the complex with the BTK enzyme. Our lead compounds show desirable PK profiles and efficacy in the preclinical rat collagen induced arthritis model.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS

The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.

ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.